株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

抗生物質の世界市場;2017年〜2021年

Global Antibiotics Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 312950
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
SALE 2017年12月31日まで 期間限定キャンペーン
Back to Top
抗生物質の世界市場;2017年〜2021年 Global Antibiotics Market 2017-2021
出版日: 2017年09月08日 ページ情報: 英文 118 Pages
概要

世界における抗生物質市場は、2017年から2021年の間、2.16%のCAGRで拡大することが見込まれています。

当レポートでは、世界における抗生物質市場の現況と将来予測、作用機序、化学的分類別の動向、市場の成長要因と課題、主要ベンダーの分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場調査手法

第4章 イントロダクション

  • 市場動向の概略

第5章 抗生物質の概要

  • イントロダクション
  • 抗生物質の作用機序
  • 抗生物質仕様の一般原則
  • 抗生物質の臨床用途
  • 感染症の疫学
  • 抗生物質の使用

第6章 獣医用医薬品の承認プロセス

  • 動物用抗生物質
  • 新規の動物用薬品申請とサプリメント
  • 略式の新規薬品申請とサプリメント
  • 条件付きの新規動物用薬品申請

第7章 抗生物質耐性の概要

  • 抗生物質耐性の原因
  • 抗生物質耐性の発達
  • 抗生物質耐性の蔓延
  • 抗生物質開発促進のイニシアチブ

第8章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 パイプライン情勢

  • Gepotidacin
  • MK-3415A
  • Amikacin Inhale
  • Carbavance
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • ARIKAYCE
  • Cadazolid
  • Ozenoxacin

第10章 化学的分類別の市場区分

  • ベータラクタム
  • マクロライド
  • キノロン
  • その他

第11章 薬物の原料

  • 天然
  • 半合成
  • 合成

第12章 作用機序別の市場区分

  • 静菌性抗生物質
  • 殺菌性抗生物質

第13章 適用別の市場区分

  • ヒト用抗生物質
  • 家畜用抗生物質

第14章 薬効範囲(スペクトル)別の市場区分

  • 広域スペクトル抗生物質
  • 狭域スペクトル抗生物質

第15章 地理区分

  • 市場概要
  • アジア太平洋地域
  • 南北アメリカ
  • 欧州・中東・アフリカ

第16章 意思決定構造

第17章 市場成長因子と課題

第18章 市場動向

第19章 ベンダー情勢

  • 競合シナリオ

第20章 主要ベンダーの分析

  • Allergan
  • GlaxoSmithKline
  • Merck
  • Pfizer1
  • その他の有力なベンダー

第21章 付録

  • 略語リスト

図表

図表
  • Exhibit 01: Overview of mechanism of action of antibiotics
  • Exhibit 02: Mechanism of action of antibiotics
  • Exhibit 03: General principles involved in the use of antibiotics
  • Exhibit 04: Clinical use of antibiotics for treatment of various common infections
  • Exhibit 05: Types of HAIs 2016
  • Exhibit 06: Causes of antibiotic resistance
  • Exhibit 07: Transfer of antibiotic-resistant strain
  • Exhibit 08: Development of antibiotic resistance
  • Exhibit 09: Spread of antibiotic resistance
  • Exhibit 10: Antibiotic resistance scenario in the US
  • Exhibit 11: Initiatives to facilitate antibiotic development
  • Exhibit 12: Global antibiotics market snapshot
  • Exhibit 13: Global antibiotics market revenue 2016-2021 ($ millions)
  • Exhibit 14: Opportunity analysis of global antibiotics market
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Pipeline landscape of global antibiotics market 2016
  • Exhibit 17: Key clinical trials
  • Exhibit 18: Segmentation of global antibiotics market by chemical class 2016
  • Exhibit 19: Segmentation of global antibiotics market share by chemical class 2016
  • Exhibit 20: Cephalosporin segmentation by generation of drugs
  • Exhibit 21: Segmentation Global antibiotics market by drug origin 2016
  • Exhibit 22: Segmentation of global antibiotics market by mechanism of action 2016
  • Exhibit 23: Segmentation of global antibiotics market by application 2016
  • Exhibit 24: Segmentation of global antibiotics market by spectrum 2016
  • Exhibit 25: Global antibiotics market share by spectrum 2016
  • Exhibit 26: Global broad-spectrum antibiotics market 2016-2021 ($ millions)
  • Exhibit 27: Global narrow-spectrum antibiotics market 2016-2021 ($ millions)
  • Exhibit 28: Segmentation of global antibiotics market share by geography 2016 and 2021
  • Exhibit 29: Segmentation of global antibiotics market revenue by geography 2016-2021
  • Exhibit 30: Segmentation of global antibiotics market share by geography 2016-2021 (%)
  • Exhibit 31: Antibiotics market scenario in different regions
  • Exhibit 32: Market scenario in APAC
  • Exhibit 33: Antibiotics market in APAC 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in Americas
  • Exhibit 35: Antibiotics market in Americas 2016-2021 ($ millions)
  • Exhibit 36: Legislation regulating antibiotic use in US
  • Exhibit 37: Market scenario in EMEA
  • Exhibit 38: Antibiotics market in EMEA 2016-2021 ($ millions)
  • Exhibit 39: Antibiotic-resistant strains according to the period of development of resistance
  • Exhibit 40: Antibiotic drug approvals versus time interval
  • Exhibit 41: Competitive structure analysis of global antibiotics market 2016
  • Exhibit 42: Allergan: Key highlights
  • Exhibit 43: Allergan: Strength assessment
  • Exhibit 44: Allergan: Strategy assessment
  • Exhibit 45: Allergan: Opportunity assessment
  • Exhibit 46: GlaxoSmithKline: Key highlights
  • Exhibit 47: GlaxoSmithKline: Strength assessment
  • Exhibit 48: GlaxoSmithKline: Strategy assessment
  • Exhibit 49: GlaxoSmithKline: Opportunity assessment
  • Exhibit 50: Merck: Key highlights
  • Exhibit 51: Merck: Strength assessment
  • Exhibit 52: Merck: Strategy assessment
  • Exhibit 53: Merck: Opportunity assessment
  • Exhibit 54: Pfizer: Key highlight
  • Exhibit 55: Pfizer: Strength assessment
  • Exhibit 56: Pfizer: Strategy assessment
  • Exhibit 57: Pfizer: Opportunity assessment

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR14623

About Antibiotics

An antibiotic is a chemical compound that kills or slows down the growth of any disease-causing microorganisms such as bacteria, parasite, and fungi but is not effective against viruses and prions. The term "antibiotic" was originally coined to refer to any compound of microbial origin that is antagonistic to the growth of the microbe. Antibiotics act via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis.

Technavio's analysts forecast the global antibiotics market to grow at a CAGR of 2.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global antibiotics market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Antibiotics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • GlaxoSmithKline
  • Merck
  • Pfizer

Other prominent vendors

  • Abbott
  • Achaogen
  • Actelion Pharmaceuticals
  • AmpliPhi Biosciences
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Basilea Pharmaceutica
  • Bayer HealthCare
  • Biocon
  • Bristol-Myers Squibb
  • Cempra
  • Cipher Pharmaceuticals
  • CordenPharma
  • Chiesi Farmaceutici
  • Eli Lilly
  • Exoxemis
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Incepta Pharmaceuticals
  • InSite Vision
  • Insmed
  • Johnson & Johnson
  • Humanigen
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Lytix Biopharma
  • Melinta Therapeutics
  • Mylan
  • Nektar
  • Orchid Pharma
  • Par Pharmaceutical
  • Paratek Pharmaceuticals
  • Pernix Therapeutics
  • PTC Therapeutics
  • RedHill
  • Sagent Pharmaceuticals
  • Sanofi
  • Shionogi
  • Starpharma
  • Sun Pharmaceutical
  • Symbiomix
  • Takeda Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • The Medicines Company
  • Valneva
  • Wockhardt

Market driver

  • Rising prevalence of infectious diseases
  • For a full, detailed list, view our report

Market challenge

  • Development of antibiotic-resistant strains
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances and mergers and acquisitions (M&A)
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Antibiotics: An overview

  • Introduction
  • Mechanism of action of antibiotics
  • General principles for the use of antibiotics
  • Clinical use of antibiotics
  • Epidemiology of infections
  • Application of antibiotics

PART 06: Veterinary drug approval process

  • Animal antibiotics
  • NADAs and supplements
  • ANADAs and supplements
  • CNADAs

PART 07: Antibiotic resistance: An overview

  • Cause of antibiotic resistance
  • Development of antibiotic resistance
  • Spread of antibiotic resistance
  • Initiatives to facilitate antibiotic development

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Pipeline landscape

  • Gepotidacin
  • MK-3415A
  • Amikacin Inhale
  • Carbavance
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • ARIKAYCE
  • Cadazolid
  • Ozenoxacin

PART 10: Market segmentation by chemical class

  • Beta-lactams
  • Macrolides
  • Quinolones
  • Others

PART 11: Market segmentation by drug origin

  • Natural
  • Semisynthetic
  • Synthetic

PART 12: Market segmentation by mechanism of action

  • Bacteriostatic
  • Bactericidal

PART 13: Market segmentation by application

  • Antibiotics for human use
  • Antibiotics for veterinary use

PART 14: Market segmentation by spectrum

  • Broad-spectrum antibiotics
  • Narrow-spectrum antibiotics

PART 15: Geographical segmentation

  • Market overview
  • Antibiotics market in APAC
  • Antibiotics market in Americas
  • Antibiotics market in EMEA

PART 16: Decision framework

PART 17: Drivers and challenges

  • Market drivers
  • Market challenges

PART 18: Market trends

  • Strategic alliances and mergers and acquisitions (M&A)
  • Patient assistance programs (PAPs)
  • Increased federal and institutional funding on antibiotic research

PART 19: Vendor landscape

  • Competitive scenario

PART 20: Key vendor analysis

  • Allergan
  • GlaxoSmithKline
  • Merck
  • Pfizer1
  • Other prominent vendors

PART 21: Appendix

  • List of abbreviations
Back to Top